After listening to the enterprise AI specialist's latest earnings call, I have some concerns over where the company is headed ...

C3.ai's growth is fairly modest given its size and the strength of the demand environment. Read why I remain neutral on AI ...

Investors should always rely on their own analysis, not just management talk and projections, when deciding whether to buy a ...

Cannabinoid-focused biopharmaceutical company C3 Pharmaceuticals announces a planned listing on the Canadian Securities ...

The new iteration of C3 Pharmaceuticals, Inc. announced that it executed a tailored Share Subscription Agreement (SSA) with ...

Shares of C3.ai Inc. AI sank 0.26% to $23.27 Wednesday, on what proved to be an all-around grim trading session for the stock ...

This was the stock's fourth consecutive day of gains.

Following the drop in its stock price, C3.ai trades at a forward price-to-sales (P/S) ratio that is just about 7 based on ...

One of the biggest headwinds looming for C3.ai: whether Baker Hughes, its most important customer, extends its partnership in ...

Let's review those challenges and see if it's the right time to buy or sell C3.ai's stock while it's still trading about 50% ...

C3.ai, Inc. (AI) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...

US Strategic Metals (USSM) has teamed up with Chilean Cobalt Corp. (C3) and Glencore AG, a subsidiary of Glencore, for US ...